Phathom Pharmaceuticals (PHAT) Enterprise Value (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Enterprise Value data on file, last reported at -$183.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 14.6% year-over-year to -$183.8 million in Q1 2026; TTM through Mar 2026 was -$183.8 million, a 14.6% increase from a year earlier, with the FY2025 full-year figure at -$132.8 million, up 55.74% from the prior year.
• Enterprise Value for Q1 2026 stood at -$183.8 million, down from -$132.8 million in the prior quarter.
• Over the last five years, Enterprise Value for PHAT reached as high as -$130.1 million in Q1 2023 and fell as low as -$384.3 million in Q4 2023.
• Historically, Enterprise Value has averaged -$220.1 million across 5 years, with a median of -$207.9 million in 2022.
• Across the five-year window, Enterprise Value plunged 149.92% in 2024 and jumped 59.11% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$155.9 million in 2022, then slumped by 146.49% to -$384.3 million in 2023, then rose by 21.89% to -$300.1 million in 2024, then surged by 55.74% to -$132.8 million in 2025, then slumped by 38.34% to -$183.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$183.8 million in Q1 2026, -$132.8 million in Q4 2025, and -$138.0 million in Q3 2025.